AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 5795804
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 mg, 10 mg)
Trial: 27080998
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (ES) of auricular acupressure, performed twice a week for 4 weeks at each acupoint for 30 seconds.
Trial: 19372329
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 4 ng/mL (Group R4)
Trial: 19372329
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2 ng/mL (Group R2)
Trial: 19372329
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 3 ng/mL (Group R3)
Trial: 19372329
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1 ng/mL (Group R1)
Trial: 11672921
Drug: 7-valent conjugate
RxNorm normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent conjugate vaccine (conjugate-conjugate)
Trial: 11672921
Drug: 7-valent conjugate
RxNorm normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (conjugate-polysaccharide)
Trial: 9039508
Drug: Methylprednisolone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (4 mg/kg/day)
Trial: 3111615
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate (1 g twice daily)
Trial: 22302136
Drug: Once-weekly etanercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly etanercept (OW) 25 mg
Trial: 22302136
Drug: Twice-weekly etanercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly etanercept (TW) 25 mg
Trial: 15881624
Drug: Quetiapine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine treatment (up to 600 mg/day)
Trial: 15881624
Drug: Quetiapine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine treatment
Trial: 12021647
Drug: Superior ophthalmic
RxNorm normalized name: Sus scrofa superior gastric plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superior ophthalmic vein dilation
Trial: 10705056
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid 500 mg q8h orally for 7 days
Trial: 10705056
Drug: No anti-staphylococcal
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-staphylococcal treatment (Control)
Trial: 17225720
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid treatment
Trial: 8443851
Drug: Rocuronium cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium cumulative dose-response
Trial: 30321440
Drug: Psychosensory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosensory therapy (Havening)
Trial: 30321440
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no psychosensory therapy)
Trial: 24436454
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine at 4.5 months
Trial: 22974788
Drug: Enalapril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (ACE inhibitor) for 6 weeks
Trial: 18998329
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids therapy (beclomethasone dipropionate or fluticasone propionate)
Trial: 15738024
Drug: Antibiotics effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics effective against Chlamydia (excluded from analysis)
Trial: 15738024
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (control group of women not receiving antibiotics)
Trial: 10642678
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (200 microg/kg body weight)
Trial: 10642678
Drug: Topical permethrin
RxNorm normalized name: permethrin Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical permethrin cream (5%)
Trial: 8839911
Drug: EO9 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EO9 12 mg/m2 weekly (arm A)
Trial: 8839911
Drug: EO9 22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EO9 22 mg/m2 every three weeks (arm B)
Trial: 26778544
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (PJ) 200 mL/d for 21 days
Trial: 26778544
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice diluted 1:1 with water (PJD) 200 mL/d for 21 days
Trial: 24266855
Drug: Reduced-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose cyclosporine (rCsA) with sirolimus and corticosteroids
Trial: 24266855
Drug: Standard-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclosporine (sCsA) with sirolimus and corticosteroids
Trial: 22908696
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid tablets
Trial: 9096964
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and glyburide (1.25-2.5 mg/day)
Trial: 3516511
Drug: muzolimine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine, 20 mg/day
Trial: 3516511
Drug: hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day
Trial: 30304013
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release (ER) onapristone 50 mg BID
Trial: 30304013
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release 100 mg QD
Trial: 24387919
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A - scan delay of 65 s after starting contrast injection over 30 s
Trial: 24387919
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B - scan delay of 105 s after starting contrast injection over 70 s
Trial: 24387919
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C - scan delay of 145 s after starting contrast injection over 110 s
Trial: 16567931
Drug: Warfarin (adjusted-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose, INR 1.4-2.8)
Trial: 12587093
Drug: NRTI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI therapy
Trial: 12587093
Drug: Control (treatment-naive)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (treatment-naive)
Trial: 10879578
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment (4 sessions of relaxation and stimulus control)
Trial: 8792889
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine 2.5 mg/ml with 3 mg of morphine (Group I)
Trial: 8792889
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine 2.5 mg/ml (Group II)
Trial: 8792889
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml isotonic saline with 3 mg morphine (Group III)
Trial: 8792889
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of isotonic saline (placebo, Group IV)
Trial: 1627201
Drug: sertaconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertaconazole 1% cream
Trial: 1627201
Drug: sertaconazole 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertaconazole 2% cream
Trial: 18823217
Drug: Etravirine 100
RxNorm normalized name: etravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 100 mg after a fasted state
Trial: 18823217
Drug: Etravirine 100
RxNorm normalized name: etravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 100 mg after a light breakfast (croissant)
Trial: 18823217
Drug: Etravirine 100
RxNorm normalized name: etravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 100 mg after an enhanced-fiber breakfast
Trial: 18823217
Drug: Etravirine 100
RxNorm normalized name: etravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 100 mg after a high-fat breakfast
Trial: 14724827
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily 1 week before chemotherapy (group 1)
Trial: 14724827
Drug: Deferred lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Deferred lamivudine treatment until serological evidence of hepatitis B virus reactivation (group 2)
Trial: 14724827
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment (group 1)
Trial: 16685181
Drug: Early Intensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Intensive Behavioral Treatment (EIBT)
Trial: 11737006
Drug: Intramuscular needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular needle insertions into six designated trigger points
Trial: 11737006
Drug: Subcutaneous insertions
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insertions (Control)
Trial: 9008270
Drug: Didanosine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine (200 mg q 12h) for 3 days, followed by didanosine (200 mg q 12h) and ciprofloxacin (750 mg q 12h) for 3 days, and then another course of didanosine (200 mg q 12h for 3 days)
Trial: 9008270
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg q 12h) for 3 days, followed by the combination with didanosine, and then ciprofloxacin (750 mg q 12h for 3 days)
Trial: 8353827
Drug: Levoprotiline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levoprotiline (150 mg)
Trial: 8353827
Drug: Maprotiline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (150 mg)
Trial: 3621988
Drug: Diflunisal (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (1000 mg daily)
Trial: 27974114
Drug: Porcine pulmonary
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine pulmonary surfactant (PS) + budesonide suspension (0.25 mg/kg)
Trial: 24355814
Drug: Spot-on formulation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spot-on formulation containing polyunsaturated fatty acids (PUFAs) and essential oils
Trial: 10780315
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg + Bezafibrate 400 mg
Trial: 10780315
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg + Bezafibrate 400 mg
Trial: 10780315
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Fluvastatin + Bezafibrate)
Trial: 26814241
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin combined with lidocaine injection for 14 days (IE-Tr)
Trial: 26814241
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin combined with lidocaine injection for 14 days (ES-Tr)
Trial: 26814241
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin combined with lidocaine injection (ES-Tr)
Trial: 26814241
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin combined with lidocaine injection (IE-Tr)
Trial: 26814241
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin combined with lidocaine injection (IE-Tr and ES-Tr)
Trial: 11323542
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment (twice a day ferrous iron, equivalent to 2 x 100 mg elemental iron)
Trial: 3285832
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg torasemide
Trial: 3285832
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg torasemide
Trial: 3285832
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg torasemide (increased to 20 mg)
Trial: 29432518
Drug: Biannual structured
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual structured medication reviews by physician, pharmacist, and nurse.
Trial: 25130998
Drug: Lapatinib (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1500 mg)
Trial: 25130998
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg)
Trial: 25130998
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus Trastuzumab (lapatinib 1000 mg, trastuzumab same dose as single agent)
Trial: 22720689
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of gentamicin in combination with metronidazole 30 to 60 minutes prior to operation
Trial: 22720689
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of gentamicin and metronidazole for 24 hours post-operation
Trial: 15951466
Drug: NN414 (0.625-12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN414 (0.625-12.5 mg/kg)
Trial: 7562241
Drug: Cyclosporin G
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin G (CsG) at low dose (5 mg/kg/day)
Trial: 7562241
Drug: Cyclosporin G
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin G (CsG) at high dose (10 mg/kg/day)
Trial: 7562241
Drug: Cyclosporin G
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin G (CsG) during tapering to lower doses
Trial: 2109330
Drug: 35% CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% CO2 in oxygen inhalation
Trial: 6791936
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous injection of synthetic salmon calcitonin (2-200 i.u.)
Trial: 6791936
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of synthetic salmon calcitonin (10-200 i.u. thrice weekly for up to 2 months)
Trial: 6791936
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of synthetic salmon calcitonin
Trial: 6791936
Drug: Calcium absorption
RxNorm normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium absorption (six studies) during treatment
Trial: 27981804
Drug: SAP therapy
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP therapy
Trial: 26547349
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg/kg loading dose, followed by 0.3 µg·kg(‐1)·h(‐1) continuous infusion)
Trial: 24371021
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 40 mg/day
Trial: 24371021
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 60 mg/day
Trial: 24371021
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) 80 mg/day
Trial: 24371021
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride modified-release (MPH-LA) (all doses combined)
Trial: 22954329
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with locking plates for two-part fractures
Trial: 22954329
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for two-part fractures
Trial: 22954329
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with Philos locking plate for multi-fragmented fractures
Trial: 22954329
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for multi-fragmented fractures
Trial: 17700217
Drug: Gliclazide (G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (G III)
Trial: 17700217
Drug: Diet (G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet (G IV)
Trial: 17700217
Drug: Glibenclamide (G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (G II)
Trial: 17700217
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (G I)
Trial: 11600559
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (5.8-6.5 mmol/liter)
Trial: 11600559
Drug: Higher rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher rates of glucose infusion (up to 8.7 mmol/liter)
Trial: 7947503
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment (10,000 i.u. initially, then 5000 i.u. twice weekly until miscarriage or the tenth week of pregnancy)
Trial: 7947503
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment in women with follicular phase luteinising hormone > 10 iu/l
Trial: 7947503
Drug: hCG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG treatment with clomiphene for ovulation induction
Trial: 7947503
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in women with follicular phase luteinising hormone > 10 iu/l
Trial: 2644594
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics after hospital discharge
Trial: 2644594
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral antibiotics after hospital discharge
Trial: 23291509
Drug: modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint-induced movement therapy followed by bimanual training (mCIMT-BiT)
Trial: 16689010
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-infective and symptomatic therapy only)
Trial: 9869019
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 mg)
Trial: 12658059
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lisinopril and nifedipine GITS
Trial: 9024279
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) bolus and NS infusion
Trial: 9024279
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) bolus (4 mg) and NAL infusion (2 mg/h)
Trial: 9024279
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) bolus and oCRH infusion (1 microgram/kg.h; maximum, 75 micrograms/h)
Trial: 9024279
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone (NAL) bolus and both NAL and oCRH infusions